Abstract

BackgroundNucleic acid amplification testing (NAT) for blood screening has been previously performed in some countries to determine NAT yields. The current study sought to explore the non-discriminating reactive NAT yields using individual-NAT (ID-NAT) and characteristics of HBV NAT yields through a 10-year retrospective analysis in Zhejiang, China.MethodsBlood donations were analyzed using individual-NAT mode by the transcription-mediated amplification (TMA) method. Supplementary HBV serological tests were performed using chemiluminescent immunoassay, and HBV viral load assay was performed by real-time polymerase chain reaction. Follow-up studies were performed in partial donors with low HBV viral loads.ResultsNon-discriminating reactive NAT yields and HBV NAT yields varied in different years. The yields ranged from 853.73 per million to 2018.68 per million and 624.60 per million to 1669.50 per million, respectively. In the 476 NAT yields, 19 were probable window periods (WP), 33 probable occult hepatitis B virus infections (OBIs), 409 were confirmed OBIs and 15 were chronic HBV infections. ID-NAT results were categorized in four groups, and the findings showed that the levels of HBV DNA viral loads were different in the four different groups (χ2 = 275.02, p < 0.01). HBV viral load distribution was significantly different between anti-HBs positive and anti-HBc positive samples (χ2 = 49.429, p < 0.01). Notably, only 42.03% donors were NAT repeated positive in the 138 repeat donors’ follow up tests.ConclusionNAT screening of blood donations can reduce the risk of transfusion-transmitted HBV infections. Positive proportions of anti-HBs and anti-HBc are correlated with the HBV viral load level. However, low level of viral load donors pose risks in HBV NAT assays, and show fluctuating state for HBV viral load and leads to non-repeated NAT results during follow up studies.

Highlights

  • Nucleic acid amplification testing (NAT) for blood screening has been previously performed in some countries to determine NAT yields

  • Total Hepatitis B virus (HBV) NAT yields in blood donations A total of 1,160,355 blood donations were analyzed by Individual donation (ID)-NAT from August 1, 2010 to December 31, 2019

  • 3042 NAT yields donations were obtained based on the initial reactive results with exception of two Hepatitis C virus (HCV) and three Human immunodeficiency virus (HIV) NAT yields

Read more

Summary

Introduction

Nucleic acid amplification testing (NAT) for blood screening has been previously performed in some countries to determine NAT yields. Hepatitis B virus (HBV) infection is a major public health concern in the world. The global hepatitis report by World Health Organization (WHO) in 2017 shows that approximately 3.5% of the world’s population has chronic HBV infection. Approximately 786,000 people die every year from liver failure, cirrhosis and primary. Wu et al BMC Infect Dis (2021) 21:714 liver cancer caused by HBV infection [1]. HBV infection is the tenth leading cause of death [1]. The positive rate of HBV surface antigen (HBsAg) decreased from approximately 9.75% in 1992 to less than 3.00% in 2014 [2, 3]. Approximately 80 million people are HBsAg positive owing to the large population of China

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.